Description
Ovagen is a synthetic tripeptide bioregulator with the sequence Glu-Asp-Leu (EDL), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its primary tissue targets are hepatocytes and gastrointestinal epithelial cells — a dual hepatic-GI tissue profile that distinguishes it within the Khavinson specialty research peptide series. Like other bioregulators in this class, Ovagen enters the cell nucleus and interacts with specific DNA promoter regions to modulate gene expression. In hepatocytes, the documented targets include CYP450 enzyme family members, glutathione S-transferase genes, and bile acid homeostasis regulators — liver metabolic function genes specifically, rather than the chromatin remodeling targets that define Livagen’s hepatic research profile.
Key Characteristics
- Dual hepatic-GI tissue targeting distinguishes Ovagen from other liver-focused Khavinson bioregulators. Where Livagen targets liver and lymphocyte populations, Ovagen’s second tissue focus is gastrointestinal epithelium, connecting it to mucosal barrier integrity and digestive tract gene regulation research alongside its hepatic applications
- CYP450 and glutathione S-transferase gene expression are among the documented hepatic targets. These Phase I and Phase II detoxification enzyme genes are specific to hepatocyte metabolic function, giving Ovagen a research angle in liver metabolism and biotransformation biology distinct from the chromatin remodeling focus of other Khavinson liver compounds
- PepT1 and PepT2 transporter-mediated cellular uptake is documented — connecting Ovagen to the same di/tripeptide transporter system relevant in KPV research, and providing a defined cellular entry mechanism that researchers using GI epithelial cell models need to account for in study design
- GI mucosal barrier integrity research is a secondary but distinct angle — preclinical data documents effects on epithelial cell turnover and mucosal gene expression in gastrointestinal tissue, making Ovagen relevant in gut biology research independently of its hepatic applications
- All published evidence is preclinical and concentrated within the Khavinson research network; no independent Western clinical trials have been conducted
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. As a tripeptide, Ovagen is susceptible to proteolytic degradation under suboptimal conditions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Ovagen?
Ovagen (EDL) is a synthetic tripeptide bioregulator from the Khavinson series targeting hepatocytes and gastrointestinal epithelial cells. It enters cell nuclei and modulates gene expression at specific DNA promoter regions, with documented targets including CYP450 family enzymes, glutathione S-transferase genes, and GI mucosal barrier proteins. All published evidence is preclinical.
How does Ovagen differ from Livagen in liver research?
Both are Khavinson bioregulators with liver tissue as a primary target, but their second tissue focus diverges entirely. Livagen (KEDA) targets lymphocytes alongside hepatocytes — its liver research connects to immune cell biology and chromatin decondensation in aged leukocyte populations. Ovagen (EDL) targets gastrointestinal epithelium alongside hepatocytes — its research spans hepatic metabolic enzyme gene regulation and GI mucosal barrier biology. Researchers select between them based on whether the study requires hepatic-immune or hepatic-GI dual tissue observation.
Why is PepT1/PepT2 transporter uptake relevant to Ovagen’s GI research applications?
PepT1 and PepT2 are di/tripeptide transporters expressed at high levels on intestinal epithelial cells — the same transport system relevant in KPV research in the GI context. Their active transport of Ovagen across epithelial membranes provides a defined cellular uptake mechanism in GI models, which affects concentration-response relationships and tissue distribution in intestinal research designs. Researchers using Ovagen in GI epithelial models need to account for this transporter-mediated uptake rather than assuming passive diffusion kinetics.
